Higher fecal immunochemical test cutoff levels: Lower positivity rates but still acceptable detection rates for early-stage colorectal cancers

Cancer Epidemiology Biomarkers and Prevention

Volumn 20, Issue 2, 2011, Pages 272-280

  Terhaar Sive Droste, Jochim S ^a   Oort, Frank A ^a   Van Der Hulst, René W M ^b   Van Heukelem, Henk A ^c   Loffeld, Ruud J L F ^d   Van Turenhout, Sietze T ^a   Larbi, Ilhame Ben ^a   Kanis, Shannon L ^a   Neerincx, Maarten ^a   Räkers, Mirre ^a   Coupé, Veerle M H ^a   Bouman, Anneke A ^a   Meijer, Gerrit A ^a   Mulder, Chris J J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Gastroenterology and Hepatology   (Netherlands)

^c SLOTERVAART HOSPITAL   (Netherlands)

^d ZAANS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SCREENING; CANCER STAGING; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; EARLY CANCER; FECAL IMMUNOCHEMICAL TEST; FECES ANALYSIS; FEMALE; HUMAN; IMMUNOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; COLONOSCOPY; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FECES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MASS SCREENING; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE;

EID: 79951663159     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-10-0848     Document Type: Article

References (32)

1. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472-7. (Pubitemid 26400242)
2. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecaloccult-blood test. Lancet 1996;348:1467-71. (Pubitemid 26400241)
3. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993;328:1365-71. (Pubitemid 23131388)
4. Guittet L, Bouvier V, Mariotte N, Vallee JP, Arsène D, Boutreux S, et al. Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut 2007;56:210-4.
5. Dancourt V, Lejeune C, Lepage C, Gailliard MC, Meny B, Faivre J. Immunochemical faecal occult blood tests are superior to guaiac-based tests for the detection of colorectal neoplasms. Eur J Cancer 2008;44:2254-8.
6. van Rossum LG, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, van Krieken HH, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008;135:82-90. (Pubitemid 351899018)
7. Hol L, Wilschut JA, van Ballegooijen M, van Vuuren AJ, van der Valk H, Reijerink JC, et al. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br J Cancer 2009;100:1103-10.
8. Oort FA, Terhaar Sive Droste JS, Van Der Hulst RW, van Heukelem HA, Loffeld RJ, Wesdorp IC, et al. Colonoscopy controlled intraindividual comparisons to screen relevant neoplasia - fecal immunochemical test versus guaiac based fecal occult blood test. Aliment Pharmacol Ther 2010;31:432-9.
9. Vilkin A, Rozen P, Levi Z, Waked A, Maoz E, Birkenfeld S, et al. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test. Am J Gastroenterol 2005;100:2519-26.
10. Grazzini G, Visioli CB, Zorzi M, Ciatto S, Banovich F, Bonanomi AG, et al. Immunochemical faecal occult blood test: number of samples and positivity cut-off. What is the best strategy for colorectal cancer screening? Br J Cancer 2009;100:259-65.
11. Launoy GD, Bertrand HJ, Berchi C, Talbourdet VY, Guizard AV, Bouvier VM, et al. Evaluation of an immunochemical fecal occult blood test with automated reading in screening for colorectal cancer in a general average-risk population. Int J Cancer 2005;115:493-6. (Pubitemid 40663756)
12. Hundt S, Haug U, Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med 2009;150:162-9.
13. Ransohoff DF. What is the role of iFOBT in screening for colorectal cancer? Gut 2007;56:1343-4.
14. Pignone M, Campbell MK, Carr C, Phillips C. Meta-analysis of dietary restriction during fecal occult blood testing. Eff Clin Pract 2001;4:150-6.
15. Rozen P, Waked A, Vilkin A, Levi Z, Niv Y. Evaluation of a desk top instrument for the automated development and immunochemical quantification of fecal occult blood. Med Sci Monit 2006;12:MT27-32.
16. Rex DK, Kahi CJ, Levin B, Smith RA, Bond JH, Brooks D, et al. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2006;130:1865-71.
17. Winawer SJ, Zauber AG, O'Brien MJ, Ho MN, Gottlieb L, Sternberg SS, et al. Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. The National Polyp Study Workgroup. N Engl J Med 1993;328:901-6. (Pubitemid 23086641)
18. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC (American Joint Committee on Cancer) Cancer Staging Manual. 7th ed. New York: Springer-Verlag; 2002.
19. Imperiale TF. Quantitative immunochemical fecal occult blood tests: is it time to go back to the future? Ann Intern Med. 2007;146:309-11.
20. van Rossum LG, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, Jansen JB, et al. Cut-off value determines the performance of a semiquantitative immunochemical faecal occult blood test in a colorectal cancer screening programme. Br J Cancer 2009;101:1274-81.
21. Levi Z, Rozen P, Hazazi R, Vilkin A, Waked A, Maoz E, et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med 2007;146:244-55. (Pubitemid 351650610)
22. Health Council of the Netherlands. Population-Based Screening for Colorectal Cancer . The Hague, the Netherlands: Health Council of the Netherlands; 2009. Publication No. 2009/13.
23. Guittet L, Bouvier V, Mariotte N, Vallee JP, Levillain R, Tichet J, et al. Performance of immunochemical faecal occult blood test in colorectal cancer screening in average-risk population according to positivity threshold and number of samples. Int J Cancer 2009;125:1127-33.
24. Brecht JG, Robra BP. A graphic method of estimating the specificity of screening programmes from incomplete follow-up data. Methods Inf Med 1987;26:53-8.
25. Altman D. Practical Statistics for Medical Research . 8th ed. New York: Chapman & Hall/CRC; 1991. p.409-3.
26. De Groot MH. Probability and Statistics . 2nd ed. Menlo Park, CA: Addison Wesley & Longman; 1989.
27. Dutch Registry of Comprehensive Cancer Centres. Available from: http://www.ikcnet.nl.
28. Ransohoff DF, Feinstein AR. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N Engl J Med 1978;299:926-30 (Pubitemid 9050459)
29. Bafandeh Y, Khoshbaten M, Eftekhar Sadat AT, Farhang S. Clinical predictors of colorectal polyps and carcinoma in a low prevalence region: results of a colonoscopy based study. World J Gastroenterol 2008;14:1534-8. (Pubitemid 351460167)
30. Pepin C, Ladabaum U. The yield of lower endoscopy in patients with constipation: survey of a university hospital, a public county hospital, and a Veterans Administration medical center. Gastrointest Endosc 2002;56:325-32.
31. van Turenhout ST, van Rossum LG, Oort FA, Laheij RJ, van Rijn AF, Terhaar sive Droste JS, et al. Is the performance of a faecal occult blood test really different in a referred population compared with a screening population?Gut 2009;58Suppl II:A297.
32. Harmston C, Akwei S, Barnes R, Goodyear S, Wong L. Are screen detected colorectal cancers asymptomatic?Colorectal Dis. 2010;12:416-9.